FDA Grants Appeal for Lytenava, Finds Substantial Effectiveness in nAMD
OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (2.6× avg).
Summary
The FDA has granted Outlook Therapeutics' appeal for its lead drug, ONS-5,010/Lytenava, finding substantial evidence of effectiveness for neovascular age-related macular degeneration (nAMD). This positive development follows a previous Complete Response Letter from the FDA and recent discussions regarding the drug's approval pathway. The company plans to resubmit its Biologics License Application (BLA) in June 2026. This news is critical for Outlook Therapeutics, which has recently faced significant financial challenges, including a going concern warning and substantial dilution from capital raises. A successful resubmission and potential approval could be transformative for the company's future.
At the time of this announcement, OTLK was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.